Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $128.0 million.

  • Stoke Therapeutics' Cash & Equivalents fell 44.41% to $83.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.4 million, marking a year-over-year decrease of 44.41%. This contributed to the annual value of $128.0 million for FY2024, which is 33.15% down from last year.
  • Stoke Therapeutics' Cash & Equivalents amounted to $128.0 million in FY2024, which was down 33.15% from $191.4 million recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Cash & Equivalents peaked at $191.4 million during FY2023, and registered a low of $113.6 million during FY2022.
  • For the 3-year period, Stoke Therapeutics' Cash & Equivalents averaged around $144.3 million, with its median value being $128.0 million (2024).
  • Per our database at Business Quant, Stoke Therapeutics' Cash & Equivalents skyrocketed by 68.59% in 2023 and then plummeted by 33.15% in 2024.
  • Stoke Therapeutics' Cash & Equivalents (Yearly) stood at $113.6 million in 2022, then surged by 68.59% to $191.4 million in 2023, then slumped by 33.15% to $128.0 million in 2024.